1
|
Uhr K, Prager-van der Smissen WJC, Heine AAJ, Ozturk B, Smid M, Göhlmann HWH, Jager A, Foekens JA, Martens JWM. Understanding drugs in breast cancer through drug sensitivity screening. SPRINGERPLUS 2015; 4:611. [PMID: 26543746 PMCID: PMC4628005 DOI: 10.1186/s40064-015-1406-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Accepted: 10/06/2015] [Indexed: 01/18/2023]
Abstract
With substantial numbers of breast tumors showing or acquiring treatment resistance, it is of utmost importance to develop new agents for the treatment of the disease, to know their effectiveness against breast cancer and to understand their relationships with other drugs to best assign the right drug to the right patient. To achieve this goal drug screenings on breast cancer cell lines are a promising approach. In this study a large-scale drug screening of 37 compounds was performed on a panel of 42 breast cancer cell lines representing the main breast cancer subtypes. Clustering, correlation and pathway analyses were used for data analysis. We found that compounds with a related mechanism of action had correlated IC50 values and thus grouped together when the cell lines were hierarchically clustered based on IC50 values. In total we found six clusters of drugs of which five consisted of drugs with related mode of action and one cluster with two drugs not previously connected. In total, 25 correlated and four anti-correlated drug sensitivities were revealed of which only one drug, Sirolimus, showed significantly lower IC50 values in the luminal/ERBB2 breast cancer subtype. We found expected interactions but also discovered new relationships between drugs which might have implications for cancer treatment regimens.
Collapse
Affiliation(s)
- Katharina Uhr
- />Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, ‘s-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands
| | - Wendy J. C. Prager-van der Smissen
- />Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, ‘s-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands
| | - Anouk A. J. Heine
- />Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, ‘s-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands
| | - Bahar Ozturk
- />Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, ‘s-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands
| | - Marcel Smid
- />Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, ‘s-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands
| | - Hinrich W. H. Göhlmann
- />Division of Janssen Pharmaceutica, Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Agnes Jager
- />Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, ‘s-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands
| | - John A. Foekens
- />Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, ‘s-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands
| | - John W. M. Martens
- />Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Postbus 2040, ‘s-Gravendijkwal 230, 3000 CA Rotterdam, The Netherlands
| |
Collapse
|
2
|
[Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer. Highlights from the 2011 ASCO Congress]. HNO 2012; 60:398, 400-3. [PMID: 22570003 DOI: 10.1007/s00106-011-2464-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Increasing interest in the treatment of locally advanced and already metastasized thyroid cancer is reflected in the high number of submitted and accepted conference papers at the annual meeting of the American Society of Clinical Oncology (ASCO Congress) 2011. Many patients suffering from differentiated, undifferentiated and medullary thyroid cancer do not respond to established therapeutic procedures, so that new strategies have to be developed. Targeted biological agents are a new and promising therapeutic method that selectively affects complex signaling cascades, especially angiogenesis, of the malignant cells. Clinicians and researchers should understand the potential of these therapeutic strategies and be aware of the typical side effects.
Collapse
|